BAK1 (Q16611) variants and mutations
BAK1 (also known as Q16611) is a human protein-coding gene encoding a bcl-2 homologous antagonist/killer protein. It promotes mitochondrial outer-membrane permeabilization during intrinsic apoptosis by oligomerizing after activation by pro-apoptotic signals. Loss or suppression can increase resistance to cell death, whereas excessive activation can contribute to tissue injury. This analysis covers 414 BAK1 variants and mutations. Of these, 86% have computational variant effect predictions. Disease context includes B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia, and type 2 diabetes mellitus. Example BAK1 variants include A2V, S3L, and G6R.
Variant analysis overview
- Gene: BAK1
- Protein: Q16611
- UniProt accession: Q16611
- Organism: Homo sapiens
- Variants analyzed: 414
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 222 unspecified-consequence records; 19 frameshift variants; 90 missense variants; 70 synonymous variants; 2 in-frame deletions; 3 splice-region variants; 6 stop-gained variants; 2 substitution
- Prediction scores: 354 variants have prediction scores (86% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia, type 2 diabetes mellitus, thrombocytopenia 4, rheumatoid arthritis, hemorrhagic disease, primary biliary cholangitis, prostate carcinoma, sunburn, testicular cancer, Hodgkins lymphoma, plasma cell myeloma.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 2 binding sites; 1 post-translational modification sites.
- Structural context: 38 variants have structural context.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable BAK1 variants
Examples include A2V, S3L, G6R, G8S, E13D, E13K, E13Q, C14F. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2V (p.Ala2Val), gnomAD rs1375591844, REVEL 0.06, CADD 23.60
- S3L (p.Ser3Leu), rs531594065, 1000Genomes rs531594065, ExAC rs531594065, TOPMed rs531594065, REVEL 0.24, CADD 27.80, Variant assessed as somatic; moderate impact.
- G6R (p.Gly6Arg), TOPMed rs1686292915, gnomAD rs1686292915, REVEL 0.09, CADD 24.20
- G8S (p.Gly8Ser), gnomAD rs1188548906, REVEL 0.11, CADD 22.70
- E13D (p.Glu13Asp), Ensembl rs1762868268, REVEL 0.02, CADD 0.06
- E13K (p.Glu13Lys), TOPMed rs986407872, gnomAD rs986407872, REVEL 0.06, CADD 20.50
- E13Q (p.Glu13Gln), TOPMed rs986407872, gnomAD rs986407872, REVEL 0.04, CADD 18.90
- C14F (p.Cys14Phe), ExAC rs754274553, TOPMed rs754274553, gnomAD rs754274553, REVEL 0.11, CADD 18.10
- C14G (p.Cys14Gly), TOPMed rs1171102208
- C14S (p.Cys14Ser), TOPMed rs1171102208
- C14Y (p.Cys14Tyr), ExAC rs754274553, TOPMed rs754274553, gnomAD rs754274553, REVEL 0.10, CADD 21.60
- G15R (p.Gly15Arg), ExAC rs761327603, TOPMed rs761327603, gnomAD rs761327603, REVEL 0.10, CADD 13.90
- E16K (p.Glu16Lys), ExAC rs773859939, TOPMed rs773859939, gnomAD rs773859939, REVEL 0.07, CADD 15.30
- E16Q (p.Glu16Gln), ExAC rs773859939, TOPMed rs773859939, gnomAD rs773859939, REVEL 0.09, CADD 14.50
- P17S (p.Pro17Ser), TOPMed rs1762867255, REVEL 0.01, CADD 1.00
- A18V (p.Ala18Val), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, REVEL 0.07, CADD 6.97, Variant assessed as somatic; moderate impact.
- L19R (p.Leu19Arg), 1000Genomes rs549441758, TOPMed rs549441758, gnomAD rs549441758, REVEL 0.05, CADD 1.15
- P20S (p.Pro20Ser), gnomAD rs1762867039, REVEL 0.06, CADD 0.23
- E24A (p.Glu24Ala), gnomAD rs1469508274
- E24G (p.Glu24Gly), gnomAD rs1469508274, REVEL 0.15, CADD 31.00
- E25K (p.Glu25Lys), gnomAD rs1307766428, REVEL 0.04, CADD 23.00
- E25E (p.Glu25Glu), gnomAD 6-33575924-C-T, CADD 13.00
- E25G (p.Glu25Gly), gnomAD 6-33575925-T-C, REVEL 0.07, MetaLR 0.01
- Q26P (p.Gln26Pro), gnomAD 6-33575915-GGCTAC, CADD 32.00
- Q26Q (p.Gln26Gln), gnomAD 6-33575921-C-T, CADD 10.30, SIFT 0.00
- Q26R (p.Gln26Arg), gnomAD 6-33575922-T-C, REVEL 0.07, MetaLR 0.02
- V27V (p.Val27Val), gnomAD 6-33575918-T-G, CADD 4.63, SIFT 0.48
- V27* (p.Val27Ter), gnomAD 6-33575919-AC-A, CADD 32.00
- A28V (p.Ala28Val), rs4987115, ClinGen CA3759594, cosmic curated COSV62349, ClinVar RCV000879093, REVEL 0.11, CADD 20.20, Benign, not provided
- Q29H (p.Gln29His), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, TOPMed rs1367979509, gnomAD rs1367979509, REVEL 0.05, CADD 22.60, Variant assessed as somatic; moderate impact.
- Q29R (p.Gln29Arg), TOPMed rs1762837733, REVEL 0.06, CADD 6.02
- T31A (p.Thr31Ala), rs1164845782, ClinGen CA363655243, ClinVar RCV004423842, gnomAD rs1164845782, REVEL 0.07, CADD 18.40, Uncertain significance, not specified
- T31I (p.Thr31Ile), Ensembl rs1582066469
- T31T (p.Thr31Thr), gnomAD 6-33575906-T-G, CADD 1.67
- E32G (p.Glu32Gly), rs747643368, gnomAD 6-33575902-CCT-C, CADD 28.60
- E32E (p.Glu32Glu), rs756559288, gnomAD 6-33575903-C-T, CADD 11.10, SIFT 0.08
- E32K (p.Glu32Lys), gnomAD 6-33575905-C-T, REVEL 0.11, MetaLR 0.01
- E33A (p.Glu33Ala), TOPMed rs1411515999
- E33K (p.Glu33Lys), gnomAD 6-33575902-C-T, REVEL 0.10, MetaLR 0.01
- V34G (p.Val34Gly), Ensembl rs1582066443
- V34F (p.Val34Phe), rs1561831579, gnomAD 6-33575898-AC-A, CADD 28.00
- F35F (p.Phe35Phe), gnomAD 6-33575894-G-A, CADD 12.30, SIFT 1.00
- R36C (p.Arg36Cys), ExAC rs750765569, TOPMed rs750765569, gnomAD rs750765569, REVEL 0.11, CADD 23.20
- R36H (p.Arg36His), 1000Genomes rs201643389, ExAC rs201643389, TOPMed rs201643389, gnomAD rs201643389, REVEL 0.03, CADD 15.40, Uncertain significance, not specified
- R36R (p.Arg36Arg), rs375549037, gnomAD 6-33575891-G-A, CADD 10.40
- S37G (p.Ser37Gly), gnomAD 6-33575890-T-C, REVEL 0.17, MetaLR 0.02
- Y38* (p.Tyr38Ter), ESP rs372257626, ExAC rs372257626, TOPMed rs372257626, gnomAD rs372257626, CADD 36.00
- Y38C (p.Tyr38Cys), TOPMed rs1012494393, gnomAD rs1012494393, REVEL 0.27, CADD 26.30
- Y38Y (p.Tyr38Tyr), rs372257626, gnomAD 6-33575885-G-A, CADD 8.89, SIFT 0.00
- V39I (p.Val39Ile), rs764068634, ClinGen CA3759587, ClinVar RCV004423839, ExAC rs764068634, REVEL 0.08, CADD 22.20, Uncertain significance, not specified
- Y41* (p.Tyr41Ter), Ensembl rs1762836835
- Y41C (p.Tyr41Cys), Ensembl rs1234273757
- Y41S (p.Tyr41Ser), Ensembl rs1234273757
- Y41L (p.Tyr41Leu), rs778587427, gnomAD 6-33575877-T-TA, CADD 32.00
- R42C (p.Arg42Cys), cosmic curated COSV10652, ESP rs368815273, ExAC rs368815273, TOPMed rs368815273, REVEL 0.22, CADD 32.00
- R42H (p.Arg42His), rs1051911, cosmic curated COSV62349, UniProt VAR 048417, gnomAD rs1051911, REVEL 0.08, CADD 26.70, Variant assessed as somatic; moderate impact.
- R42R (p.Arg42Arg), rs1762836691, gnomAD 6-33575873-G-T, CADD 10.70, SIFT 0.00
- Q44* (p.Gln44Ter), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; high impact.
- Q44Q (p.Gln44Gln), rs1762836642, gnomAD 6-33575867-C-T, CADD 12.00, SIFT 0.00
- Q44L (p.Gln44Leu), gnomAD 6-33575868-T-A, REVEL 0.14, MetaLR 0.01
- E46K (p.Glu46Lys), TOPMed rs959610391, gnomAD rs959610391, REVEL 0.14, CADD 29.00
- Q47* (p.Gln47Ter), gnomAD 6-33575860-G-A, CADD 36.00, SIFT 0.00
- E48* (p.Glu48Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E48D (p.Glu48Asp), ExAC rs769950150, gnomAD rs769950150, REVEL 0.06, CADD 19.40
- E48G (p.Glu48Gly), Ensembl rs1561831528
- E48K (p.Glu48Lys), ExAC rs775583296, TOPMed rs775583296, gnomAD rs775583296, REVEL 0.17, CADD 25.30
- E48E (p.Glu48Glu), rs769950150, gnomAD 6-33575855-C-T, CADD 11.70
- A49G (p.Ala49Gly), gnomAD rs1286126080, REVEL 0.05, CADD 19.60
- A49S (p.Ala49Ser), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; moderate impact.
- A49V (p.Ala49Val), gnomAD rs1286126080, REVEL 0.04, CADD 18.70
- A49P (p.Ala49Pro), gnomAD 6-33575854-C-G, REVEL 0.07, MetaLR 0.04
- G51E (p.Gly51Glu), ExAC rs772953650, TOPMed rs772953650, gnomAD rs772953650, REVEL 0.10, CADD 19.40
- G51R (p.Gly51Arg), ExAC rs760488257, gnomAD rs760488257, REVEL 0.14, CADD 24.50
- G51G (p.Gly51Gly), rs1324626047, gnomAD 6-33575846-C-G, CADD 9.04
- G51A (p.Gly51Ala), gnomAD 6-33575847-C-G, REVEL 0.07, MetaLR 0.03
- V52A (p.Val52Ala), gnomAD rs1051912
- V52E (p.Val52Glu), gnomAD rs1051912
- V52G (p.Val52Gly), cosmic curated COSV62349, gnomAD rs1051912
- V52M (p.Val52Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A53T (p.Ala53Thr), TOPMed rs1280525161, gnomAD rs1280525161, REVEL 0.10, CADD 16.90
- A53V (p.Ala53Val), cosmic curated COSV62349, ESP rs375013861, ExAC rs375013861, TOPMed rs375013861, REVEL 0.03, CADD 15.30
- A53P (p.Ala53Pro), rs768325698, gnomAD 6-33575838-GCAGC-, CADD 24.50
- A54G (p.Ala54Gly), TOPMed rs1561831487, REVEL 0.06, CADD 9.63
- A54T (p.Ala54Thr), Ensembl rs1762835967
- A54V (p.Ala54Val), TOPMed rs1561831487, REVEL 0.03, CADD 8.69
- A54A (p.Ala54Ala), gnomAD 6-33575837-G-T, CADD 7.96
- P55A (p.Pro55Ala), TOPMed rs1160330534, gnomAD rs1160330534, REVEL 0.08, CADD 20.20
- A56V (p.Ala56Val), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, REVEL 0.03, CADD 12.20, Variant assessed as somatic; moderate impact.
- A56A (p.Ala56Ala), rs143727127, gnomAD 6-33575831-G-A, CADD 1.36
- A56G (p.Ala56Gly), gnomAD 6-33575832-G-C, REVEL 0.03, MetaLR 0.01
- A56D (p.Ala56Asp), gnomAD 6-33575832-G-T, REVEL 0.06, MetaLR 0.01
- D57E (p.Asp57Glu), TOPMed rs1762835642, REVEL 0.15, CADD 18.50
- D57N (p.Asp57Asn), cosmic curated COSV10970, ExAC rs778549210, TOPMed rs778549210, gnomAD rs778549210, REVEL 0.09, CADD 19.90
- D57D (p.Asp57Asp), gnomAD 6-33575828-G-A, CADD 9.85
- D57Y (p.Asp57Tyr), gnomAD 6-33575830-C-A, REVEL 0.12, MetaLR 0.02
- P58P (p.Pro58Pro), rs768052277, gnomAD 6-33575825-T-C, CADD 6.20
- P58S (p.Pro58Ser), gnomAD 6-33575827-G-A, REVEL 0.18, MetaLR 0.03
- E59* (p.Glu59Ter), Ensembl rs1490626880
- M60T (p.Met60Thr), ExAC rs748774801, gnomAD rs748774801, REVEL 0.16, CADD 23.00
- V61A (p.Val61Ala), NCI-TCGA Cosmic COSV6234, cosmic curated COSV62349, Variant assessed as somatic; moderate impact.
- T62P (p.Thr62Pro), Ensembl rs1582066332
- T62I (p.Thr62Ile), gnomAD 6-33575814-G-A, REVEL 0.07, MetaLR 0.01
- P64T (p.Pro64Thr), TOPMed rs1762835317
- P64P (p.Pro64Pro), rs377347576, gnomAD 6-33575807-A-G, CADD 5.88
- P64H (p.Pro64His), gnomAD 6-33575808-G-T, REVEL 0.02, MetaLR 0.00
- L65L (p.Leu65Leu), rs1449757286, gnomAD 6-33575806-G-A, CADD 5.40
- Q66Q (p.Gln66Gln), gnomAD 6-33575801-T-C, CADD 0.62
- Q66K (p.Gln66Lys), gnomAD 6-33575803-G-T, REVEL 0.11, MetaLR 0.00
- S68N (p.Ser68Asn), ESP rs371989238, TOPMed rs371989238, gnomAD rs371989238, REVEL 0.04, CADD 0.03
- S68C (p.Ser68Cys), gnomAD 6-33575797-T-A, REVEL 0.02, MetaLR 0.01
- S69N (p.Ser69Asn), ExAC rs755786933, TOPMed rs755786933, gnomAD rs755786933, REVEL 0.07, CADD 42.00
- S69R (p.Ser69Arg), rs5745592, UniProt VAR 018830, Ensembl rs5745592, REVEL 0.12, CADD 23.90
- T70S (p.Thr70Ser), ExAC rs747344615, gnomAD rs747344615, REVEL 0.07, CADD 22.50
- T70T (p.Thr70Thr), gnomAD 6-33575438-G-A, CADD 18.10, SIFT 0.07
- M71K (p.Met71Lys), TOPMed rs1333827871, gnomAD rs1333827871, REVEL 0.05, CADD 18.30
- M71R (p.Met71Arg), TOPMed rs1333827871, gnomAD rs1333827871, REVEL 0.06, CADD 19.40
- M71V (p.Met71Val), 1000Genomes rs528797429, ExAC rs528797429, gnomAD rs528797429, REVEL 0.09, CADD 15.40
- Q73H (p.Gln73His), ExAC rs752817502, gnomAD rs752817502, REVEL 0.10, CADD 24.20
- Q73L (p.Gln73Leu), ESP rs375888869, ExAC rs375888869, TOPMed rs375888869, gnomAD rs375888869, REVEL 0.10, CADD 23.00
- Q73A (p.Gln73Ala), rs34017174, gnomAD 6-33575431-G-GC, CADD 33.00
- Q73* (p.Gln73Ter), gnomAD 6-33575431-G-A, CADD 40.00
- V74A (p.Val74Ala), ExAC rs755256768, gnomAD rs755256768, REVEL 0.18, CADD 28.20
- V74G (p.Val74Gly), ExAC rs755256768, gnomAD rs755256768
- V74M (p.Val74Met), rs765284813, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62349, ExAC rs765284813, REVEL 0.17, CADD 26.70, Uncertain significance, not specified
- V74V (p.Val74Val), rs754059376, gnomAD 6-33575426-C-T, CADD 17.70
- R76Q (p.Arg76Gln), rs761535491, ExAC rs761535491, gnomAD rs761535491, REVEL 0.09, CADD 23.80, Variant assessed as somatic; moderate impact.
- R76W (p.Arg76Trp), cosmic curated COSV62349, ExAC rs766561404, gnomAD rs766561404, REVEL 0.14, CADD 31.00, Uncertain significance, not specified
- Q77H (p.Gln77His), ExAC rs763976645, TOPMed rs763976645, gnomAD rs763976645, REVEL 0.07, CADD 23.10
- Q77Q (p.Gln77Gln), rs763976645, gnomAD 6-33575417-C-T, CADD 19.20, SIFT 0.22
- Q77* (p.Gln77Ter), gnomAD 6-33575419-G-A, CADD 39.00
- L78L (p.Leu78Leu), rs1236518329, gnomAD 6-33575414-G-A, CADD 3.86, SIFT 0.07
- A79T (p.Ala79Thr), rs762960717, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62349, ExAC rs762960717, REVEL 0.12, CADD 24.90, Variant assessed as somatic; moderate impact.
- A79V (p.Ala79Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I80N (p.Ile80Asn), Ensembl rs1762827363
- I80V (p.Ile80Val), TOPMed rs1414525753
- I81L (p.Ile81Leu), TOPMed rs1049800577, REVEL 0.15, CADD 25.90
- I81I (p.Ile81Ile), rs1051913, gnomAD 6-33575405-G-A, CADD 8.23, SIFT 0.09
- G82E (p.Gly82Glu), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; moderate impact.
- G82R (p.Gly82Arg), rs775198844, ExAC rs775198844, TOPMed rs775198844, gnomAD rs775198844, REVEL 0.46, CADD 26.40, Variant assessed as somatic; moderate impact.
- D83N (p.Asp83Asn), ExAC rs769426436, TOPMed rs769426436, gnomAD rs769426436, REVEL 0.30, CADD 26.70
- D83D (p.Asp83Asp), rs745314875, gnomAD 6-33575399-G-A, CADD 1.76, SIFT 0.02
- D83T (p.Asp83Thr), rs758307806, gnomAD 6-33575400-TC-T, CADD 28.90
- D84N (p.Asp84Asn), rs892929984, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62349, TOPMed rs892929984, REVEL 0.08, CADD 23.40, Variant assessed as somatic; moderate impact.
- D84D (p.Asp84Asp), gnomAD 6-33575396-G-A, CADD 17.40, SIFT 0.05
- D84V (p.Asp84Val), gnomAD 6-33575397-T-A, REVEL 0.24, MetaLR 0.03
- I85V (p.Ile85Val), ExAC rs776437416, gnomAD rs776437416
- I85I (p.Ile85Ile), rs1762826835, gnomAD 6-33575393-G-A, CADD 18.70, SIFT 0.04
- N86D (p.Asn86Asp), rs1283682592, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62349, gnomAD rs1283682592, REVEL 0.11, CADD 22.80, Variant assessed as somatic; moderate impact.
- N86T (p.Asn86Thr), Ensembl rs1582065902
- N86N (p.Asn86Asn), gnomAD 6-33575390-G-A, CADD 17.60, SIFT 0.00
- N86S (p.Asn86Ser), gnomAD 6-33575391-T-C, REVEL 0.08, MetaLR 0.01
- R87* (p.Arg87Ter), ExAC rs770571379, TOPMed rs770571379, gnomAD rs770571379, CADD 36.00
- R87L (p.Arg87Leu), NCI-TCGA Cosmic COSV1006, REVEL 0.07, CADD 18.50, Variant assessed as somatic; moderate impact.
- R87Q (p.Arg87Gln), cosmic curated COSV10064, gnomAD rs1181539037, REVEL 0.03, CADD 14.30
- R88C (p.Arg88Cys), ExAC rs746711568, TOPMed rs746711568, gnomAD rs746711568, REVEL 0.30, CADD 28.80
- R88H (p.Arg88His), rs778171445, NCI-TCGA Cosmic COSV6234, cosmic curated COSV62349, ExAC rs778171445, REVEL 0.23, CADD 27.30, Variant assessed as somatic; moderate impact.
- Y89C (p.Tyr89Cys), ExAC rs758884894, TOPMed rs758884894, gnomAD rs758884894, REVEL 0.27, CADD 26.60
- D90D (p.Asp90Asp), rs748646933, gnomAD 6-33575378-G-A, CADD 12.30, SIFT 0.36
- S91P (p.Ser91Pro), NCI-TCGA TCGA novel, REVEL 0.13, CADD 3.69, Variant assessed as somatic; moderate impact.
- E92V (p.Glu92Val), rs1165454774, gnomAD 6-33575371-ACT-A, CADD 32.00
- E92D (p.Glu92Asp), gnomAD 6-33575372-C-G, REVEL 0.06, MetaLR 0.00
- Q94* (p.Gln94Ter), TOPMed rs958587510, CADD 37.00
- Q94H (p.Gln94His), gnomAD 6-33575366-C-G, REVEL 0.03, MetaLR 0.01
- Q94R (p.Gln94Arg), rs1238547388, gnomAD 6-33575367-TG-T, CADD 29.00
- T95I (p.Thr95Ile), gnomAD 6-33575364-G-A, REVEL 0.04, MetaLR 0.00
- T95N (p.Thr95Asn), gnomAD 6-33575364-G-T, REVEL 0.03, MetaLR 0.00
- M96I (p.Met96Ile), gnomAD rs1423887173, REVEL 0.09, CADD 19.20
- M96T (p.Met96Thr), Ensembl rs1762826164
- Q98* (p.Gln98Ter), ESP rs371320117, ExAC rs371320117, TOPMed rs371320117, gnomAD rs371320117, CADD 36.00
- Q98E (p.Gln98Glu), ESP rs371320117, ExAC rs371320117, TOPMed rs371320117, gnomAD rs371320117, REVEL 0.03, CADD 16.60
- Q98R (p.Gln98Arg), 1000Genomes rs563897863, ExAC rs563897863, gnomAD rs563897863, REVEL 0.03, CADD 22.20
- H99D (p.His99Asp), ESP rs377341171, ExAC rs377341171, TOPMed rs377341171, gnomAD rs377341171, REVEL 0.03, CADD 20.70
- L100L (p.Leu100Leu), rs1762825884, gnomAD 6-33575348-C-T, CADD 13.30, SIFT 0.03
- L100Q (p.Leu100Gln), gnomAD 6-33575349-A-T, REVEL 0.37, MetaLR 0.06
- Q101K (p.Gln101Lys), ExAC rs766540475, TOPMed rs766540475, gnomAD rs766540475, REVEL 0.11, CADD 23.60
- Q101P (p.Gln101Pro), Ensembl rs1762825790
- Q101R (p.Gln101Arg), gnomAD 6-33575346-T-TGC, CADD 32.00
- P102L (p.Pro102Leu), ExAC rs756326673, gnomAD rs756326673
- P102P (p.Pro102Pro), gnomAD 6-33574510-G-T, CADD 21.40, SIFT 1.00
- P102H (p.Pro102His), gnomAD 6-33574511-G-T, CADD 18.10, SIFT 0.33
Public BAK1 analysis runs
- BAK1 analysis run — BAK1 (414 variants) — completed 2026-08-22